Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-38. (cancelled)

Claim 39. (new) A method of treating a subject suffering from depression comprising administering to the subject a therapeutically effective amount of a compound having the structure:



;

wherein each R_1 is independently hydrogen; -F; -Cl; -Br; -I; -CN; $-NO_2$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; aryl; heteroaryl; $-N(R_5)_2$; $-(CH_2)_mOR_5$; $-COR_5$; $-CO_2R_5$; $-OCOR_5$; $-CON(R_5)_2$; $-N(R_5)COR_5$; $-N(R_5)CON(R_5)_2$; $-OCON(R_5)_2$ or $-N(R_5)CO_2R_5$;

wherein R_2 is hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; $-NH_2$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1

wherein R_3 is hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1; or wherein R_2 and R_3 together can be $-(CH_2)_p-$;

wherein R_4 is straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, C_3-C_6 cycloalkyl, C_1-C_7 alkyl-C_3-C_6 cycloalkyl; $-N(R_5)_2$ or $-(CH_2)_mOR_5$;

wherein each R_5 is independently hydrogen; aryl; heteroaryl or straight chained or branched C_1-C_7 alkyl, wherein the alkyl may be substituted with an aryl or heteroaryl;

wherein each R_6 is independently hydrogen; straight chained or branched C_1-C_7 alkyl;

wherein each R_7 is independently hydrogen; phenyl or straight chained or branched C_1-C_7 alkyl, wherein the alkyl may be substituted with a phenyl;

wherein each m is independently an integer from 0 to 5 inclusive;

wherein n is an integer from 1 to 5 inclusive;

wherein p is an integer from 2 to 7 inclusive;

wherein q is an integer from 0 to 2 inclusive; and

wherein each X is independently CR_1 or N, provided that if one X is N then the remaining X are CR_1;

or a pharmaceutically acceptable salt thereof.

Claim 40. (new) The method of claim 39, wherein the compound has the structure:



Claim 41. (new) The method of claim 40, wherein the compound has the structure:



;

wherein R_2 and R_3 are each independently hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl;

aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1; or wherein R_2 and R_3 together can be $-(CH_2)_p-$;

wherein R_4 is straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, C_3-C_6 cycloalkyl, $-N(R_5)_2$ or $-(CH_2)_mOR_5$; and X is CH or N.

Claim 42. (new) The method of claim 41, wherein X is CH.

Claim 43. (new) The method of claim 41, wherein X is N.

Claim 44. (new) A method of treating a subject suffering from anxiety comprising administering to the subject a therapeutically effective amount of a compound having the structure:



;

wherein each R_1 is independently hydrogen; -F; -Cl; -Br; -I; -CN; $-NO_2$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; aryl; heteroaryl; $-N(R_5)_2$; $-(CH_2)_mOR_5$; $-COR_5$; $-CO_2R_5$; $-OCOR_5$; $-CON(R_5)_2$; $-N(R_5)COR_5$; $-N(R_5)CON(R_5)_2$; $-OCON(R_5)_2$ or $-N(R_5)CO_2R_5$;

wherein R_2 is hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; $-NH_2$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1

wherein R_3 is hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1; or wherein R_2 and R_3 together can be $-(CH_2)_p-$;

wherein R_4 is straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, C_3-C_6 cycloalkyl, C_1-C_7 alkyl-C_3-C_6 cycloalkyl; $-N(R_5)_2$ or $-(CH_2)_mOR_5$;

wherein each R_5 is independently hydrogen; aryl; heteroaryl or straight chained or branched C_1-C_7 alkyl, wherein the alkyl may be substituted with an aryl or heteroaryl;

wherein each R_6 is independently hydrogen; straight chained or branched C_1-C_7 alkyl;

wherein each R_7 is independently hydrogen; phenyl or straight chained or branched C_1-C_7 alkyl, wherein the alkyl may be substituted with a phenyl;

wherein each m is independently an integer from 0 to 5 inclusive;

wherein n is an integer from 1 to 5 inclusive;

wherein p is an integer from 2 to 7 inclusive;

wherein q is an integer from 0 to 2 inclusive; and

wherein each X is independently CR_1 or N, provided that if one X is N then the remaining X are CR_1;

or a pharmaceutically acceptable salt thereof.

Claim 45. (new) The method of claim 44, wherein the compound has the structure:



Claim 46. (new) The method of claim 45, wherein the compound has the structure:



wherein R_2 and R_3 are each independently hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1; or wherein R_2 and R_3 together can be $-(CH_2)_p-$;

wherein R_4 is straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, C_3-C_6 cycloalkyl, $-N(R_5)_2$ or $-(CH_2)_mOR_5$; and X is CH or N.

Claim 47. (new) The method of claim 46, wherein X is CH.

Claim 48. (new) The method of claim 46, wherein X is N.

Claim 49. (new) A method of treating a subject suffering from obesity comprising administering to the subject a therapeutically effective amount of a compound having the structure:



;

wherein each R_1 is independently hydrogen; -F; -Cl; -Br; -I; -CN; $-NO_2$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; aryl; heteroaryl; $-N(R_5)_2$; $-(CH_2)_mOR_5$; $-COR_5$; $-CO_2R_5$; $-OCOR_5$; $-CON(R_5)_2$; $-N(R_5)COR_5$; $-N(R_5)CON(R_5)_2$; $-OCON(R_5)_2$ or $-N(R_5)CO_2R_5$;

wherein R_2 is hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; $-NH_2$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1

wherein R_3 is hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the

aryl or heteroaryl may be substituted with one or more R_1; or wherein R_2 and R_3 together can be $-(CH_2)_p-$;

wherein R_4 is straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, C_3-C_6 cycloalkyl, C_1-C_7 alkyl-C_3-C_6 cycloalkyl; $-N(R_5)_2$ or $-(CH_2)_mOR_5$;

wherein each R_5 is independently hydrogen; aryl; heteroaryl or straight chained or branched C_1-C_7 alkyl, wherein the alkyl may be substituted with an aryl or heteroaryl;

wherein each R_6 is independently hydrogen; straight chained or branched C_1-C_7 alkyl;

wherein each R_7 is independently hydrogen; phenyl or straight chained or branched C_1-C_7 alkyl, wherein the alkyl may be substituted with a phenyl;

wherein each m is independently an integer from 0 to 5 inclusive;

wherein n is an integer from 1 to 5 inclusive;

wherein p is an integer from 2 to 7 inclusive;

wherein q is an integer from 0 to 2 inclusive; and

wherein each X is independently CR_1 or N, provided that if one X is N then the remaining X are CR_1;

or a pharmaceutically acceptable salt thereof.

Claim 50. (new) The method of claim 49, where the compound has the structure:



Claim 51. (new) The method of claim 50, wherein the compound has the structure:



wherein R_2 and R_3 are each independently hydrogen; -F; -Cl; -Br; -I; -CN; $-(CH_2)_mOR_5$; $-(CH_2)_mSR_5$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R_1; or wherein R_2 and R_3 together can be $-(CH_2)_p-$;

wherein R_4 is straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl, C_3-C_6 cycloalkyl, $-N(R_5)_2$ or $-(CH_2)_mOR_5$; and X is CH or N.

Claim 52. (new) The method of claim 51, wherein X is CH.

Claim 53. (new) The method of claim 51, wherein X is N.